Abstract
Despite numerous studies looking at antiplatelet/anticoagulation regimens after lower extremity bypass, there has been no consensus on optimal regimen for a particular combination of conduit and target. A 2017 Vascular Quality Initiative study found that anticoagulation had no effect on primary patency of infrainguinal bypass grafts but had some benefit in secondary patency of infrageniculate targets. Clinically, many patients who receive below-knee bypasses are started on anticoagulation, which historically has been with warfarin.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
